October 22, 2017 9:51 PM ET


Company Overview of Xencor, Inc.

Company Overview

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukem...

111 West Lemon Avenue

Monrovia, CA 91016

United States

Founded in 1997

83 Employees



Key Executives for Xencor, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 47
Total Annual Compensation: $516.7K
Vice President of Finance and Secretary
Age: 58
Total Annual Compensation: $327.4K
Chief Medical Officer and Senior Vice President
Age: 63
Total Annual Compensation: $460.6K
Chief Scientific Officer and Senior Vice President of Research
Age: 53
Total Annual Compensation: $370.8K
Chief Business Officer
Age: 58
Total Annual Compensation: $326.5K
Compensation as of Fiscal Year 2016.

Xencor, Inc. Key Developments

INmune Bio, Inc. Licenses INB03 from Xencor, Inc

INmune Bio, Inc. announced that it has licensed INB03, a novel innate immune system check-point inhibitor that targets Myeloid Derived Suppressor Cells, from Xencor, Inc. Myeloid Derived Suppressor Cells (MDSC) of the innate immune system are often increased in patients with cancer. The level of MDSC in the blood or the tumor microenvironment predict severity of disease, risk of dying from the cancer, and the failure of other immunotherapy treatment strategies such as currently available check point inhibitors. The MDSC secrete immunosuppressive cytokines that protect the tumor from attack by the patient's immune system. Strategies that target MDSC are needed to continue to make progress in the treatment of cancer.

Xencor, Inc. Presents at 2017 BIO Investor Forum, Oct-17-2017 08:30 AM

Xencor, Inc. Presents at 2017 BIO Investor Forum, Oct-17-2017 08:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Edgardo Baracchini, Chief Business Officer.

Xencor, Inc. Presents at LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology, Sep-28-2017 08:30 AM

Xencor, Inc. Presents at LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology, Sep-28-2017 08:30 AM. Venue: Lotte New York Palace, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Xencor, Inc., please visit www.xencor.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.